Selective inhibitors of ERK protein kinase and uses thereof

US7501415B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Alexander Aronov · Watertown, US
• Michael Hale · Bedford, US
• Francois Maltais · Somerville, US
• Gabriel Martinez-Botella · Wayland, US
• Judith Straub · Cambridge, US
• Qing Tang · Acton, US

Key dates

• Filing date: Dec 20, 2005
• Grant date: Mar 10, 2009
• Expiry date: Oct 10, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are compounds that are useful as ERK2 inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer.